On Monday, Shares of Advanced Micro Devices, Inc. (NASDAQ:AMD), gained 1.55% to $2.62, as the company is looking to decide whether to split itself in two or spin off a business, according to Reuters.
CEO Lisa Su is trying to turn the company around as it seeks to reverse its fortunes and compete with rival Intel (INTC), Reuters said, and one way to do it is to break away graphics and licensing from its server business.
This comes after the company posted weak first quarter 2015 results in April, with revenue of $1.03 billion and loss of 9 cents per share, contrast with revenue of $1.4 billion and a profit of 2 cents per share in the same quarter last year.
The global semiconductor company was predictable to report revenue of $1.05 billion, or loss of 5 cents per share in the first quarter of 2015, according to analysts polled by Thompson Reuters.
Advanced Micro Devices, Inc. operates as a semiconductor company worldwide. The company’s products primarily comprise x86 microprocessors as an accelerated processing unit (APU), chipsets, discrete graphics processing units (GPUs), and semi-custom System-on-Chip (SoC) products.
Shares of Merck & Co. Inc. (NYSE:MRK), inclined 1.36% to $58.83, during its last trading session, as analysts believe new drugs from Merck’s pipeline, counting treatments for cancer and Alzheimer’s diseases, could boost the company’s finances, according to Barron’s.
Shares are predictable to hit $70 in the next year, up 22% from a recent $58, Sanford C. Bernstein analyst Tim Anderson said.
One of the new drugs that has already been approved for advanced skin cancer is Keytruda, which assists patients’ immune system attack tumors, Barron’s noted. Sales hit $83 million in the latest quarter but if approved for wider use, analysts expect annual sales to reach $5 billion within six years.
Other drugs that will ring in profits comprise diabetes drug Januvia and drugs to treat Hepatitis C and HPV, the most common sexually transmitted diseases in the U.S.
Merck & Co., Inc. provides health care solutions worldwide. The company offer therapeutic and preventive agents to treat cardiovascular, type 2 diabetes, asthma, nasal allergy symptoms, allergic rhinitis, chronic hepatitis C virus, HIV-1 infection, fungal infections, intra-abdominal infections, hypertension, arthritis and pain, inflammatory, osteoporosis, male pattern hair loss, and fertility diseases.
Finally, Altria Group Inc. (NYSE:MO), ended its last trade with 0.95% gain, and closed at $49.79, as Consumer stocks were mostly higher, with shares of consumer staples companies in the S&P 500 advancing around 0.4%. Shares of consumer discretionary firms in the S&P 500 were up by about 0.5%.
Altria Group, Inc., through its auxiliaries, manufactures and sells cigarettes, smokeless products, and wine in the United States and internationally. It offers cigarettes primarily under the Marlboro brand; cigars principally under the Black & Mild brand; and moist smokeless tobacco products under the Copenhagen, Skoal, Red Seal, Husky, and Marlboro Snus brand names.
DISCLAIMER:
This article is published by www.wsnewspublishers.com. The Content included in this article is just for informational purposes only. All information used in this article is believed to be from reliable sources, but we make no representations or warranties of any kind, express or implied, about the completeness, accuracy, or reliability with respect to this article.
All visitors are advised to conduct their own independent research into individual stocks before making a purchase decision.
Information contained in this article contains forward-looking information within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934, counting statements regarding the predictable continual growth of the market for the corporation’s products, the corporation’s ability to fund its capital requirement in the near term and in the long term; pricing pressures; etc.
Any statements that express or involve discussions with respect to predictions, expectations, beliefs, plans, projections, objectives, aims, assumptions, or future events or performance may be forward looking statements. Forward-looking statements are based on expectations, estimates, and projections at the time the statements are made that involve a number of risks and uncertainties which could cause actual results or events to differ materially from those presently anticipated. Forward looking statements may be identified through the use of such words as expects, will, anticipates, estimates, believes, or by statements indicating certain actions may, could, should/might occur.
